Home › Trial NCT06528847
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
- Trial IDNCT06528847
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Pulmonary Hospital, Shanghai, China
- Enrollment62
- Start date2024-06-05
- ConditionsNon-Small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.